Hospital-acquired Pneumonia Drugs Market to Stand at US$3.8 bn by 2020 fueled by Imminent Launches

Nosocomial or hospital acquired infections have created numerous complications for patients in hospitals throughout the world, as these infections are caused by multidrug resistant microorganisms, the recuperation of a patient is drastically reduced and accompanied by several comorbidities. Being multidrug resistant, these organisms are immune to the conventional antibiotics hence difficult to treat. Pneumonia is one of the prominent infections caused in hospital premises. Cases of hospital acquired pneumonia are common in immunocompromised patients, post surgical infections, enteral feeding, elderly and infant patients. As hospital acquired pneumonia is mainly caused as a result of prolonged exposure to ventilator air, it is also called as ventilator associated pneumonia. Major causative pathogens include methicillin resistant S. aureus (MRSA), multi drug resistant (MDR) P. aeruginosa, Klebsiella and Acinetobacter. Respiratory Syncytial Virus (RSV) has also been found to be a major causative agent of nosocomial pneumonia in new borne.

Get Report Sample @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1881

The appreciable demand for hospital-acquired pneumonia falls into perspective when one considers the fact that pneumonia accounts for over 22% of all hospital-acquired infections. Often, conventional antibiotics are unable to treat multidrug resistant organisms, creating a sizeable unmet demand for effective drugs for not just hospital-acquired pneumonia but also for other kinds of hospital acquired infections.

However, the astounding amounts of money spent on combating hospital-acquired drugs has forced governments to impose strict policies to address the root causes of such infections. As many of these programs meet success, the incidence rate of hospital-acquired infections will likely see a dip. This will, in turn, lead to a decline in the demand for hospital-acquired pneumonia drugs. The report terms this trend as an impending restraint for the growth of the global hospital-acquired pneumonia drugs market.

Hospital-acquired pneumonia, which is also sometimes referred to as ventilator-associated pneumonia, is typically seen among patients who are immunocompromised patients, on enteral feeding, or have undergone surgery. Infants, too, face a risk of acquiring hospital-acquired pneumonia. Among the newborn, respiratory syncytial virus (RSV) is identified as being the major cause of nosocomial pneumonia.

The global hospital-acquired pneumonia drugs market currently features one vaccine and five investigational drugs in clinical trials phase III. It is estimated that many of these drugs will hit the market in 2017. The following drugs are currently in phase III of clinical trials, as per the report: Cubist Pharmaceuticals’ Ceftolozane/tazobactam and tedizolid phosphate, AstraZeneca PLC’s Ceftazidime/avibactam, Bayer Healthcare’s Amikacin inhale, Achaogen, Inc.’s Plazomicin, and GlaxoSmithKline’s Synflorix. Of these, tedizolid phosphate is emerging as the most preferred drug for treating nosocomial pneumonia.

View Report @ https://www.transparencymarketresearch.com/hospital-acquired-pneumonia-drugs.html

Leave a Reply